Western Suburbs Neurosciences Clinical Trials

Neurosciences Clinical Trials

Western Suburbs Neurosciences Clinical Trials

Through ongoing medical research, patients with neurological conditions are finding new ways to live longer and better. If you or someone you love is living with Parkinson’s disease, multiple sclerosis, brain tumors, a stroke, or other serious neurological disease, Northwestern Medicine offers a range of promising neuroscience clinical trials right in the community that may help improve quality of life.

If you find a clinical trial that interests you, talk with your physician or call or email the contact listed. For more information, please call 630.933.6107. TTY for the hearing impaired 630.933.4833.

Current Neuroscience Clinical Trials

Through the physicians on the medical staff at Northwestern Medicine Central DuPage Hospital and Northwestern Medicine Delnor Hospital, you have convenient access to a wide variety of neurosciences clinical trials. For ease of searching, the current research studies are sorted into the following categories:

  • Aneurysms
  • Brain Tumors
  • Humanitarian Use Devices
  • Multiple Sclerosis (MS)
  • Parkinson’s Disease
  • Stroke
  • Other Neurosciences

View Trials

Study: RAGE: Ruptured Aneurysms Treated with Hydrogel Coils. A registry study of hydrogel coils used to treat aneurysms.
Clinical Trial #: NCT03252314
Principal Investigator: Harish N. Shownkeen, MD
Contact: Robin Schmidt, MS RN, Clinical Research Study Coordinator 630.938.2625

Study: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma.
Clinical Trial #: NRG-BN001
Principal Investigator: Vinai Gondi, MD1
Contact: Edith Maritato, Study Coordinator, 630.352.5450
Learn more at Clinicaltrials.gov2


Study: A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to intermediate Grade Gliomas.
Clinical Trial #: NRG-BN005
Principal Investigator: Dr. Gondi
Contact: Edith Maritato, Study Coordinator 630.352.5450


Study: A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
Clinical Trial #: NRG-CC003
Principal Investigator: Dr. Gondi
Contact: Edith Maritato, Study Coordinator 630.352.5450


Study: A Phase II, single arm, open label trial combining Optune with concurrent Bevacizumab or Progressive Meningioma
Clinical Trial #: NU16C02
Principal Investigator: Dr. Grimm
Contact: Edith Maritato, Study Coordinator 630.352.5450


Study: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide vs. Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Clinical Trial #: N0577 (CODEL)
Principal Investigator: Dr. Gondi
Contact: Edith Maritato, Study Coordinator 630.352.5450


Study: A Phase III< Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy.
Clinical Trial #: Orbus, STELLAR Study OT-15-001
Principal Investigator: Dr. Grimm
Contact: Edith Maritato, Study Coordinator 630.352.5450


Study: Pivotal, open label, randomized study of radiosurgery with or without Tumor Treating Fields for 1-10 brain metastases from non-small cell lung cancer.
Clinical Trial #: NovoCure METIS EF-25
Principal Investigator: Dr. Gondi
Contact: Edith Maritato, Study Coordinator 630.352.5450


Study: Molecular Analysis for Therapy Choice (MATCH) for Patients with histologically documented solid tumors and lymphomas
Clinical Trial #: EAY131
Principal Investigator: Dr. Kahn
Contact: Kelly Schaffer, Study Coordinator 630.352.5450


Study: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Clinical Trial #: S1609
Principal Investigator: Dr. George
Contact: Edith Maritato, Study Coordinator 630.352.5450


Study: A Phase I study of Safety and Tolerability of Acetazolamide with Temozolomide in Adults with Newly Diagnosed MGMT Promoter-Methylated Malignant Glioma
Clinical Trial #: Protocol 18-048 BrainUp
Principal Investigator: Dr. Gondi
Contact: Edith Maritato, Study Coordinator 630.352.5450


Study: Open-label, Randomized, Controlled, Phase III Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Clinical Trial #: Protocol 100-206 Diffusion Pharmaceuticals
Principal Investigator: Dr. Grimm
Contact: Edith Maritato, Study Coordinator 630.352.5450


Study: Serum Lactate: a potential biomarker for malignant primary brain tumors and differentiator for tumor recurrence vs. radiation necrosis
Clinical Trial #: 17-049
Principal Investigator: Dr. Khan
Contact: Kelly Schaffer, Study Coordinator 630.352.5450


Study: Nervous System Tumor Bank
Clinical Trial #: 17-048
Principal Investigator: Dr. Khan
Contact: Kelly Schaffer, Study Coordinator 630.352.5450


Study: Cerebrovascular Tumor Bank
Clinical Trial #: 17-063
Principal Investigator: Dr. Khan
Contact: Kelly Schaffer, Study Coordinator 630.352.5450


Study: Cognition in Pseudoprogression Versus True Tumor Progression
Clinical Trial #: 17-053
Principal Investigator: Dr. Khan
Contact: Kelly Schaffer, Study Coordinator 630.352.5450


Study: A Pilot Study to Test Rapid Acquisition of Point of Care Ultrasound for Various Central Nervous System pathologies
Clinical Trial #: 18-045
Principal Investigator: Dr. Khan
Contact: Kelly Schaffer, Study Coordinator 630.352.5450


Study: Detection of altered cognition in brain disease via assessment of speech abnormalities as assessed by novel verbal linguistic analysis software.
Clinical Trial #: 18-046
Principal Investigator: Dr. Khan
Contact: Kelly Schaffer, Study Coordinator 630.352.5450


Study: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
Clinical Trial #: NRG-BN003
Principal Investigator: Dr. Gondi
Contact: Edith Maritato, Study Coordinator 630.352.5450

A Humanitarian Use Device (HUD) is intended for use in patients with conditions that affect less than 4,000 people in the United States and there is no comparable device marketed to treat/diagnose those conditions or diseases. Since the number of patients is so small, the Food and Drug Administration (FDA) has approved the use of HUDs for the clinical treatment of patients without the same amount of testing that other products get. The ability of this device to treat your condition has not been proven, but the FDA believes that these devices are likely to be safe and will probably benefit patients.

Aneurysm

Study: Neuroform: Microdelivery Stent System
Treatment: The Neuroform stent can be placed in a brain artery across the opening of an aneurysm. After the stent is in place, the aneurysm sac can be filled with small metal coils. The coils prevent blood from flowing into the aneurysm and could greatly reduce the risk of aneurysm rupture. The Neuroform stent is a small metallic mesh tube that is designed to keep the coils in the aneurysm sac.
Principal Investigator: Harish N. Shownkeen, MD

Learn more at FDA.gov2


Aneurysm

Study: CODMAN ENTERPRISE: TM Vascular Reconstruction Device and Delivery System
Treatment: The ENTERPRISE TM Vascular Reconstruction Device and Delivery System stent can be placed in a brain artery across the opening of an aneurysm. After the stent is in place, the aneurysm sac can be filled with small metal coils. The coils prevent blood from flowing into the aneurysm and could greatly reduce the risk of aneurysm rupture. The stent is a small metallic mesh tube that is designed to keep the coils in the aneurysm sac to aid in treating your wide-neck, intracranial, saccular or fusiform aneurysms.
Principal Investigator: Harish N. Shownkeen, MD

Learn more at FDA.gov2

Study: Verismo: Observational study of Ocrelizumab (Ocrevus) treatment in patients with Multiple Sclerosis to determine rates of breast cancer and all malignancies
Clinical Trial #: Not enrolling yet
Principal Investigator: Dr. Gutti
Contact: Seem Jain, Clinical Research Coordinator 630.933.7581

Study: RESTORE: A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion to assess Sustained effecTs Of dRoxidopa therapy
Clinical Trial #: NCT02586623
To treat patients with the following: Parkinson's Disease (PD), Multiple System Atrophy (MSA) or Pure Autonomic Failure(PAF), or Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta Hydroxylase (DBH) deficiency.
Principal Investigator: Martha T. McGraw, MD
Contact: Kathy Hansen, BSN, CNRC, Study Coordinator, 630.933.6107

Learn more at Clinicaltrials.gov2


Study: Pharma2B: This study will evaluate an oral fixed-dose, once daily product that combines pramipexole with rasagiline for the treatment of early Parkinson’s disease.
Clinical Trial #: NCT01968460
Principal Investigator: Dr. McGraw
Contact: Kathy Hansen, BSN CNRN Study Coordinator 630.933.3317


Study: Presence: Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated with Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Clinical Trial #: NCT03305809
Principal Investigator: Dr. Grujic
Contact: Kathy Hansen, BSN CNRN Study Coordinator 630.933.3317


Study: Pro-Go: This is a Phase IV, prospective, observational, post-marketing study designed to obtain additional data on the effect of XADAGO on motor and non-motor symptoms in Parkinson's Disease patients newly prescribed XADAGO.
Clinical Trial #: NCT03944785
Principal Investigator: Dr. McGraw
Contact: Kathy Hansen, BSN CNRN Study Coordinator 630.933.3317

Stroke

Study: Arcadia: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
Clinical Trial #: NCT03192215
Principal Investigator: Dr. Pandya
Contact: Robin Schmidt, MS RN Study Coordinator 630-933-2625


Study: MOST: The primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours) results in improved 90-day modified Rankin scores (mRS) as compared with placebo in acute ischemic stroke (AIS) patients treated with 0.9mg/kg IV rt-PA within three hours of symptom onset.
Clinical Trial #: NCT03735979
Principal Investigator: Dr. Sachdeva
Contact: Robin Schmidt, MS RN Study Coordinator 630-933-2625


Intracranial Hemorrhage

Study: Aspire: A randomized, double-blinded, phase III clinical trial designed to test the efficacy and safety of anticoagulation, compared with aspirin, in patients with a recent ICH and high-risk non-valvular AF (CHA2DS2-VASc score ≥ 2). Seven hundred patients will be enrolled over 3.5 years and followed for study outcomes for a minimum of 12 months and maximum of 36 months. The primary efficacy outcome is any stroke (hemorrhagic or ischemic) or death from any cause
Clinical Trial #: NCT03907046
Principal Investigator: Dr. Pandya
Contact: Robin Schmidt, MS RN Study Coordinator 630-933-2625


Study: Hemostasis and Intracranial Hemorrhage: To determine the hemostatic mechanisms of hematoma expansion after intracerebral hemorrhage (ICH), leading to specific interventions that can improve patient outcomes after ICH and other bleeding conditions (e.g. neurotrauma, Subdural hematoma).
Clinical Trial #: STU00208910
Principal Investigators: Dr. A. Naidech, Dr. J. Huml
Contact: Robin Schmidt, MS RN Study Coordinator 630-933-2625

Legal Information
1

In the spirit of keeping you well-informed, the physician(s) identified are neither agents nor employees of Northwestern Memorial HealthCare or any of its affiliate organizations. They have selected our facilities as places where they want to treat and care for their private patients.

2

By clicking on these websites, you are leaving the Northwestern Medicine website. These websites are independent resources. Northwestern Medicine does not operate or control the content of these websites. By visiting these websites, you agree to this third party’s terms of use for their website.